Tag Archives: Afrezza

Farxiga DAPA-HF receives priority review; Fiasp pediatric approval in US; MannKind launching in Brazil

A series of diabetes-related news items were observed today from AstraZeneca, Novo Nordisk, and MannKind. AZ announced FDA filing acceptance and granting of priority review for the Farxiga DAPA-HF sNDA. According to AZ, the PDUFA date is in Q2 2020. Additionally, Novo announced US approval of Fiasp for pediatric populations. Further, MannKind announced that it has received approval of the proposed price of Afrezza in Brazil, and intends to commence marketing and distribution the week of January 13, 2020. Below, FENIX provides context and insights regarding these news items.

This content is for Read Less members only.
Already a member? Log in here

MannKind Q3 ’19 Earnings Update

MannKind hosted its Q3 ’19 earnings call and provided updates to its diabetes business. Of note, MannKind disclosed a new, three-pronged strategy to drive Afrezza adoption. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Already a member? Log in here

New MannKind and Dance Inhaled Insulin Data; EASD 2019 Day 4

On the fourth day of EASD, 3 key press releases were observed including new inhaled insulin data from MannKind and Dance. Additionally, Xeris announced the initiation of its Ph2 pramlintide+insulin fixed-ratio combination trial. In case you missed it earlier today, FENIX also provided coverage of Novo’s Ph3b CONCLUDE data presentation (H2H Tresiba vs. Toujeo T2DM basal-only trial). Below FENIX provides insights and context from each respective announcement.

This content is for Read Less members only.
Already a member? Log in here

MannKind and Senseonics Q2 ’19 Earnings Updates

MannKind and Senseonics hosted their Q2 ’19 earnings calls and provided updates to their respective diabetes businesses. Below, FENIX provides highlights and insights from the calls.

This content is for Read Less members only.
Already a member? Log in here

MannKind Partners with GoodRx

MannKind announced it formed a partnership with GoodRx to “help raise awareness on ways patients can save money on their mealtime insulin.” Recall, GoodRx is a platform designed for patients without insurance or high-deductible plans to help them compare drug prices and identify savings opportunities (e.g. copay cards). Of note, the MannKind press release appears to suggest that the sole purpose of the partnership is to promote the Afrezza copay card. Below, FENIX provides brief thoughts on the MannKind partnership with GoodRx.

This content is for Read Less members only.
Already a member? Log in here